CoChat

Presentations, Causes and Outcomes of Drug-Induced Liver Injury in Egypt

Alhaddad, Omkolthoum, Elsabaawy, Maha, Abdelsameea, Eman, Abdallah, Ayat, Shabaan, Ahmed, Ehsan, Nermine, Elrefaey, Ahmed, Elsabaawy, Dalia, Salama, Mohsen · 2020 · Scientific Reports
Cited by 23

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Drug-induced liver injury (DILI) is a frequent cause of liver injury and acute liver failure. We aimed to review all hospitalized DILI cases in a tertiary Egyptian center from January 2015 through January 2016. Cases with elevated alanine aminotransferase more than 3-fold and/or alkaline phosphatase more than 2-fold the upper limit of normal value were prospectively recruited and followed for one year. Drug history, liver biopsy whenever feasible and application of Roussel Uclaf Causality Assessment Method (RUCAM) were the diagnostic prerequisites after exclusion of other etiologies of acute liver injury. In order of frequency, the incriminated drugs were: Diclofenac (31 cases, 41.3%), amoxicillin-clavulanate (14 cases, 18.7%), halothane toxicity (8 cases, 10.7%), ibuprofen (4 cases, 5.3%), Khat (3 cases, 4%), tramadol (3 cases, 4%), Sofosbuvir with ribavirin (2 cases, 2.7%), and acetylsalicylic acid (2 cases, 2.7%) with one offending drug in 93.3% of cases. Forty-four cases (58.7%) were males; while 56 cases (74.7%) had HCV related chronic liver disease. Thirty-two cases (42.7%) presented with pattern of hepatocellular injury, while 23 cases (30.7%) were with cholestasis, and 20 cases (20.7%) with a mixed hepatocellular/cholestatic injury. One case received a transplant (0.75%), 7 cases died (9.3%), 23 cases (30.6%) developed liver decompensation (hepatic encephalopathy and ascites), and 44 cases completely resolved (58.7%). In conclusion, Diclofenac is the commonest offender in DILI occurrence in an Egyptian cohort. Age and prothrombin concentration were the only predictors of unfavorable outcomes of DILI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-020-61872-9

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 27

  1. Qureshi, Z. P., Seoane-Vazquez, E., Rodriguez-Monguio, R., Stevenson, K. B. & Szeinbach, S. L. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiology drug. safety. 20(7), 772–777 (2011). · DOI
  2. Zhou, Y. et al. Epidemiology of drug induced liver injury in China a systematic analysis of the Chinese literature including 21,789 patients. Eur. J. Gastroenterol. Hepatol. 25(7), 825–829 (2013). · DOI · Paper page
  3. Aithal, G. P. et al. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther. 89(6), 806–815 (2011). · DOI · Paper page
  4. Rockey, D. C. et al. US Drug-Induced Liver Injury Network. Causality assessment in drug- induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 51(6), 2117–26 (2010). · DOI · Paper page
  5. Kovalszki, A. & Weller, P. F. Eosinophilia. Prim. Care. 43(4), 607–617 (2016). · DOI
  6. Leise, M., Poterucha, J. & Talwalkar, J. Drug-Induced Liver injury. Mayo Clin. Proceedings. 89(1), 95–106 (2014). · DOI · Paper page
  7. Lianos, L. et al. Causality assessment of liver injury after chronic oral amiodarone intake. Pharmacoepidemiol. Drug. Saf. 18(4), 291–300 (2009). · DOI
  8. Medina-Caliz, I. et al. Spanish DILI Registry. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J. Hepatology. 65(3), 532–542 (2016). · DOI · Paper page
  9. Tsutsui, A. et al. Comparison of Liver Biopsy Findings with the Digestive Disease Week Jaban 2004 Scale for Diagnosis of Drug-Induced Liver Injury. Mediators Inflamm. 913793 (2015). · DOI
  10. Sgro, C. et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 36(2), 451–55 (2002). · DOI · Paper page
  11. Suk, K. & Kim, D. Drug-induced liver injury: present and future. Clin. Mol. Hepatol. 18(3), 249–57 (2012). · DOI · Paper page
  12. Andrade, R. J. et al. Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 129(2), 512–21 (2005). · DOI · Paper page
  13. Chalasani, N. et al. Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States. Gastroenterology. 135(6), 1924–34 (2008). · DOI · Paper page
  14. Devarbhavi, H. et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am. J. Gastroenterol. 105(11), 2396–2404 (2010). · DOI · Paper page
  15. Sobhonslidsuk, A. et al. The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: a population-base study. BMC Gastroenterol. 16(1), 135 (2016). · DOI
  16. Meier, Y. et al. Incidence of drug-induced liver injury in medical inpatients. Eur. J. ClinPharmacol. 61(2), 135–43 (2005).
  17. Idilman, R. et al. The characteristics and clinical outcome of drug-induced liver injury: a single-center experience. J. ClinGastroenterol. 44(6), e128–e132 (2010).
  18. Ou, P. et al. Causes, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital. Springerplus. Dec. 22, 4:802, https://doi.org/10.1186/s40064-015-1600-8 (2015). · DOI · Paper page
  19. Licata, A., Minissale, M. G., Calvaruso, V. & Craxì, A. A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort. Eur. Rev. Med. Pharmacol. Sci. 21(1), 112–21 (2017).
  20. Betrán, A. et al. The Increasing Trend in Caesarean Section Rates: Global, Regional and National Estimates: 1990–2014. PLoS One. 11(2), e0148343 (2016). · DOI · Paper page
  21. Lucena, M. I. et al. Spanish Group for the Study of Drug-Induced Liver Disease. Phenotypic characterization of idiosyncratic drug induced liver injury: the influence of age and sex. Hepatology. 49(6), 2001–09 (2009). · DOI · Paper page
  22. Bjornsson, E. & Olsson, R. Outcome and prognostic markers in sever drug- induced liver disease. Hepatology. 42(2), 481–89 (2005). · DOI · Paper page
  23. Björnsson, E., Kalaitzakis, E. & Olsson, R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment. Pharmacol. Ther. 25(12), 1411–21 (2007). · DOI · Paper page
  24. Ibáñez, L., Pérez, E., Vidal, X. & Laporte, J. R. Grup d’Estudi Multicènteric d’Hepatotoxicitat Aguda de Barcelona (GEMHAB). Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J. Hepatol. 37(5), 592–600 (2002). · DOI
  25. Björnsson, E. & Davidsdottir, L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J. Hepatol. 50(3), 511–17 (2009). · DOI · Paper page
  26. Chalasani, N. et al. United States Drug Induced Liver Injury Network. Features and Outcomes of 899 Patients with Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology. 148(7), 1340–52 (2015). · DOI · Paper page
  27. De Valle, M. B., Av Klinteberg, V., Alem, N., Olsson, R. & Björnsson, E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment. PharmacolTher. 24(8), 1187–1195 (2006). · DOI · Paper page

Cited by

See all 23

Metadata

Authors
Alhaddad, O., Elsabaawy, M., Abdelsameea, E., Abdallah, A., Shabaan, A., Ehsan, N., Elrefaey, A., Elsabaawy, D., & Salama, M.
Venue
Scientific Reports
Published
2020-03-20
Volume
10
Issue
1
ISSN
2045-2322
Cited by
23
References
6
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Presentations, Causes and Outcomes of Drug-Induced Liver Injury in Egypt. https://app.cochat.ai/papers/10.1038/s41598-020-61872-9
The paper
Alhaddad, O., Elsabaawy, M., Abdelsameea, E., Abdallah, A., Shabaan, A., Ehsan, N., Elrefaey, A., Elsabaawy, D., & Salama, M. (2020). Presentations, Causes and Outcomes of Drug-Induced Liver Injury in Egypt. Scientific Reports. https://doi.org/10.1038/s41598-020-61872-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.